Navigation Links
Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
Date:2/15/2011

SAN DIEGO, and PARSIPPANY, N.J., Feb. 15, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that additional safety data are being highlighted from its Phase 3 trial of EXPAREL™ (bupivacaine extended-release liposome injection) in bunionectomy. The data showed comparable safety in wound healing and significantly improved efficacy in pain reduction compared to placebo. These results are being highlighted in a poster presentation at the 2011 American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, Calif.

"Data show that EXPAREL did not alter wound healing and no patients experienced malunion or non-union, both of which are critical factors considered when used to determine the appropriate postsurgical analgesic therapy," said Eugene R. Viscusi, M.D., Director, Acute Pain Management, Department of Anesthesiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia. "These data, coupled with efficacy data, demonstrate that a single administration of EXPAREL enabled more patients to be pain-free for up to 48 hours post surgery, and significantly delayed usage of, or decreased the need for opioid rescue medication. These overall findings support that EXPAREL may be a useful addition to postsurgical analgesic."

The multicenter, parallel-group, randomized, double-blind study of 193 patients evaluated the efficacy and safety of the intraoperative administration of EXPAREL compared with placebo in bunionectomy patients. The company reported preliminary efficacy data in October 2009, and presented updated efficacy data during the Orthopaedic Research Society meeting (January 2011). These study results include:

  • Statistically significantly more patients treated with EXPAREL were pain-free at 2, 4, 8 and 48 hours compared to placebo (p<0.05) and statistically
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    2. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    3. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    4. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    5. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    6. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    7. ADVENTRX Pharmaceuticals Provides Update on ANX-514
    8. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
    9. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
    10. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    11. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ("Bedrocan") ... of Directors, enhancing executive oversight and strengthening the ... licensed producer of medicinal cannabis in ... experience in producing and supplying government-regulated pharmaceutical-grade cannabis ... As previously announced in a press ...
    (Date:8/21/2014)...  Cyberonics, Inc. (NASDAQ: CYBX ) today announced ... Quarterly highlights 1   Operating results for ... quarter of fiscal 2014, and other achievements, include: , ... 6.8%; , Strong international net sales of $13.2 million, ... , U.S. net product sales reached a new high of ...
    (Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
    Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
    (Date:8/21/2014)... report that children with autism appear to have excess ... with typical children. The scientists also believe it ... synapses through drug treatment. Synapses are the points ... communicate with each other. Having excess synapses may have ... neuroscientists at Columbia University Medical Center in New York ...
    (Date:8/21/2014)... self-interest, humans do not protest being overcompensated, even ... State University,s Brains and Behavior Program have found. ... concerned than previously believed about the inequity of ... the journal Brain Connectivity . These findings ... their self-interest, indicating the interest humans show in ...
    (Date:8/21/2014)... United Benefit Advisors (UBA), the ... pleased to announce Trinity Benefit Advisors as its ... Trinity Benefit Advisors is a full service firm ... clients. Their consultative approach is comprised of four ... and monitoring. Their dedication to effective results and ...
    (Date:8/21/2014)... Centennial, CO (PRWEB) August 21, 2014 ... provider of in-home care, today announced that it has ... Care Pulse. This distinction illustrates Home Care Assistance’s commitment ... Assistance is to ensure that our client’s in the ... care available,” says Pete Lane, Owner of Home Care ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 ... Systems (Network-based, Independent, Hybrid), Maps and Navigation, ... and emergency services - Worldwide Market Forecasts ... segments the indoor location market into various ... of revenues. The report also identifies the ...
    Breaking Medicine News(10 mins):Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:Influenced by self-interest, humans less concerned about inequity to others 2Health News:Influenced by self-interest, humans less concerned about inequity to others 3Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Home Care Assistance of Centennial Receives Home Care Pulse Certified – Trusted Provider Distinction 2Health News:Home Care Assistance of Centennial Receives Home Care Pulse Certified – Trusted Provider Distinction 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 4
    ... often been associated with serious side-effects. Researchers at the ... mice, found a way of utilising the positive effects ... is acted on, current research at the Academy shows. ... PNAS (Proceedings of the National Academy of Sciences). ...
    ... bacterial DNA that often carries antibiotic resistance is a master ... widely differing bacterial species, shows a study made by ... with Chalmers University of Technology. The results are published in ... More and more bacteria are becoming resistant to our ...
    ... , MONDAY, April 11 (HealthDay News) -- Young mothers ... have children, and they also consume more saturated fat, ... Examining data from Project EAT (Eating and Activity ... of Minnesota focused on the link between parental status, ...
    ... Normal daily fluctuations in blood pressure aren,t linked with the ... heart attack or stroke in the morning, a new study ... who underwent three types of sleep/wake cycle experiments designed to ... daily rise and fall in blood pressure. In all ...
    ... pain can significantly reduce disability in older adults, according to ... newsletter from The Gerontological Society of America ... Annual Scientific Meeting in November 2010, the current WHAT,S HOT ... managing pain and preserving function, and methods to improve the ...
    ... , SUNDAY, April 10 (HealthDay News) -- Obese patients taking ... lost an average of 22 pounds over a year, while ... study has found. Qnexa is a combination of ... the United States, currently available under a variety of brand ...
    Cached Medicine News:Health News:Antibiotic resistance spreads rapidly between bacteria 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 3Health News:Effective pain management crucial to older adults' well-being 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 3Health News:Experimental Weight-Loss Drug Seems to Work: Study 4
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: